Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

NCT06211153 · clinicaltrials.gov ↗

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia With T315I Mutation

Sponsor

Novartis Pharmaceuticals